Literature DB >> 7748968

Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2.

M Engelhardt1, J A Rump, U Hellerich, R Mertelsmann, A Lindemann.   

Abstract

Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7748968     DOI： 10.1007/BF01700380

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  21 in total

Review 1.  Interleukin-2: a possible trigger for autoimmunity.

Authors:  J A Gonzalo; E Cuende; J E Alés-Martínez; C Martínez; G Kroemer
Journal:  Int Arch Allergy Immunol       Date:  1992       Impact factor: 2.749

2.  Fibromyalgia and interleukin-2 therapy for malignancy.

Authors:  D J Wallace; K Margolin; P Waller
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

Review 3.  The role of complement and its receptor in the elimination of immune complexes.

Authors:  J A Schifferli; Y C Ng; D K Peters
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

4.  Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy.

Authors:  E M Massarotti; N Y Liu; J Mier; M B Atkins
Journal:  Am J Med       Date:  1992-06       Impact factor: 4.965

Review 5.  Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way.

Authors:  S D Voss; R Hong; P M Sondel
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

6.  Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study.

Authors:  A Lindemann; P Brossart; K Höffken; M Flasshove; D Voliotis; V Diehl; G Hecker; H Wagner; R Mertelsmann
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

Review 7.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Fc gamma receptor activation of neutrophils in cryoglobulin-induced leukocytoclastic vasculitis.

Authors:  M Hundt; M Zielinska-Skowronek; R E Schmidt
Journal:  Arthritis Rheum       Date:  1993-07

9.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

Authors:  E Lotzová; C A Savary; R B Herberman
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

Review 10.  Immune-complex vasculitis: role of complement and IgG-Fc receptor functions.

Authors:  J D Smiley; S E Moore
Journal:  Am J Med Sci       Date:  1989-10       Impact factor: 2.378
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.